Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2025)

Catalyst Pharmaceuticals' Net Margin history spans 11 years, with the latest figure at 34.53% for Q4 2025.

  • For Q4 2025, Net Margin rose 175.0% year-over-year to 34.53%; the TTM value through Dec 2025 reached 36.39%, up 498.0%, while the annual FY2025 figure was 36.39%, 498.0% up from the prior year.
  • Net Margin reached 34.53% in Q4 2025 per CPRX's latest filing, down from 35.57% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 71.16% in Q4 2022 to a low of 29.96% in Q3 2023.
  • Average Net Margin over 5 years is 31.09%, with a median of 33.8% recorded in 2021.
  • Peak YoY movement for Net Margin: tumbled -11910bps in 2021, then soared 6406bps in 2024.
  • A 5-year view of Net Margin shows it stood at 24.3% in 2021, then skyrocketed by 193bps to 71.16% in 2022, then crashed by -78bps to 15.41% in 2023, then surged by 113bps to 32.78% in 2024, then increased by 5bps to 34.53% in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Net Margin are 34.53% (Q4 2025), 35.57% (Q3 2025), and 35.55% (Q2 2025).